Agnesska C. Benjamin

Agnesska C. Benjamin

Auto-generated profile, based on publicly available information

Agnesska C. Benjamin

Univerisity College London

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KSKirupa Sathasivam
Kirupa Sathasivam
ANAndreas Neueder
Andreas Neueder
TGTheresa A. Gipson
Theresa A. Gipson
CLChristian Landles
Christian Landles
ABAgnesska C. Benjamin
Agnesska C. Benjamin
GBGillian P. Bates
Gillian P. Bates
Huntington disease (HD) is a devastating, late-onset, inherited neurodegenerative disorder that manifests with personality changes, movement disorders, and cognitive decline. It is caused by a CAG repeat expansion in exon 1 of the HTT gene that translates to a polyglutamine tract in the huntingtin protein (HTT). The formation of HTT fragments has been implicated as an essential step in the molecular pathogenesis of HD and several proteases that cleave HTT have been identified. However, the importance of smaller N-terminal fragments has been highlighted by their presence in HD postmortem brains and by the fact that nuclear inclusions are only detected by antibodies to the N terminus of HTT. Despite an intense research effort, the precise length of these fragments and the mechanism by which they are generated remains unknown. Here we show that CAG repeat length–dependent aberrant splicing of exon 1 HTT results in a short polyadenylated mRNA that is translated into an exon 1 HTT protein. Given that mutant exon 1 HTT proteins have consistently been shown to be highly pathogenic in HD mouse models, the aberrant splicing of HTT mRNA provides a mechanistic basis for the molecular pathogenesis of HD. RNA-targeted therapeutic strategies designed to lower the levels of HTT are under development. Many of these approaches would not prevent the production of exon 1 HTT and should be reviewed in light of our findings.

27 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ANAndreas Neueder
Andreas Neueder
ADAnaelle A. Dumas
Anaelle A. Dumas
ABAgnesska C. Benjamin
Agnesska C. Benjamin
GBGillian P. Bates
Gillian P. Bates
Huntington’s disease is caused by a CAG repeat expansion in exon 1 of theHTTgene. We have previously shown that exon 1HTTdoes not always splice to exon 2 producing a small transcript (HTTexon1) that encodes the highly pathogenic exon 1 HTT protein. The mechanisms by which this incomplete splicing occurs are unknown. Here, we have generated a minigene system that recapitulates the CAG repeat-length dependence ofHTTexon1production, and has allowed us to define the regions of intron 1 necessary for incomplete splicing. We show that manipulation of the expression levels of the splicing factor SRSF6, predicted to bind CAG repeats, modulates this aberrant splicing event and also demonstrate that RNA polymerase II transcription speed regulates the levels ofHTTexon1production. Understanding the mechanisms by which this pathogenic exon 1 HTT is generated may provide the basis for the development of strategies to prevent its production.

30 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJeffrey Pido-Lopez
Jeffrey Pido-Lopez
RARalph Andre
Ralph Andre
ABAgnesska C. Benjamin
Agnesska C. Benjamin
NANadira Ali
Nadira Ali
SFSahar Farag
Sahar Farag
GBGillian P. Bates
Gillian P. Bates
Neurodegenerative diseases, characterised by the progressive and selective neuronal death in the central nervous system, are frequently accompanied by an activated immune system. In Huntington’s disease (HD), clinical and animal studies show evidence of immune activity, along with hyper-reactive monocyte/macrophage responses, while application of immunosuppressive regimens have imparted beneficial effects to HD mice. These findings suggest a contributory role of the immune system in HD pathology, with immune-based interventions offering a potential therapeutic strategy. Herein, we show that peripheral and CNS immune system activity increased with disease progression in HD mouse models and defined the phenotype of the immune response. Additionally, the depletion of monocytes and macrophagesin vivo, via clodronate liposome treatment, revealed a major contributory role of these innate immune cells to the chronic inflammatory milieu observed during the course of the disease. This suggests that peripheral immunomodulatory strategies targeting monocytes and macrophages could be relevant for HD.

19 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DBDale T. Bryant
Dale T. Bryant
CLChristian Landles
Christian Landles
APAikaterini S. Papadopoulou
Aikaterini S. Papadopoulou
ABAgnesska C. Benjamin
Agnesska C. Benjamin
JDJoshua K. Duckworth
Joshua K. Duckworth
GBGillian P. Bates
Gillian P. Bates
Histone Deacetylase 11 (HDAC11) is highly expressed in the central nervous system where it has been reported to have roles in neural differentiation. In contrast with previous studies showing nuclear and cytoplasmic localisation, we observed synaptic enrichment of HDAC11. Knockout mouse models for HDACs 1–9 have been important for guiding the development of isoform specific HDAC inhibitors as effective therapeutics. Given the close relationship between HDAC11 and neural cells in vitro, we examined neural tissue in a previously uncharacterised Hdac11 knockout mouse (Hdac11KO/KO). Loss of HDAC11 had no obvious impact on brain morphology and neural stem/precursor cells isolated from Hdac11KO/KO mice had comparable proliferation and differentiation characteristics. However, in differentiating neural cells we observed decreased expression of schizophrenia-associated gene Fez1 (fasciculation and elongation protein zeta 1), a gene previously reported to be regulated by HDAC11 activity. FEZ1 has been associated with the dendritic growth of neurons and risk of schizophrenia via its interaction with DISC1 (disrupted in schizophrenia 1). Examination of cortical, cerebellar and hippocampal tissue reveal decreased Fez1 expression specifically in the hippocampus of adult mice. The results of this study demonstrate that loss of HDAC11 has age dependent and brain-region specific consequences.

13 August 2021 in iScience
Verified
Journal Article
Open access
CWCharlotte M. de Winde
Charlotte M. de Winde
SGSamantha L. George
Samantha L. George
ECEva Crosas-Molist
Eva Crosas-Molist
YGYukti Hari Gupta
Yukti Hari Gupta
AAAbbey B. Arp
Abbey B. Arp
SASophie E. Acton
Sophie E. Acton
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilize amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by Rho GTPase signalling. Migrastatic drugs targeting actin polymerization and contractility are therefore a promising treatment option for metastatic melanoma. To predict amoeboid invasion and metastatic potential, biomarkers functionally linked to contractility pathways are needed. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts and is overexpressed in many cancers. We show that podoplanin enhances amoeboid invasion in melanoma. Podoplanin expression in murine melanoma drives rounded cell morphology, increasing motility, and invasion in vivo. Podoplanin expression is increased in a subset of dedifferentiated human melanoma, and in vitro is sufficient to upregulate melanoma-associated marker Pou3f2/Brn2. Together, our data define podoplanin as a functional biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.

26 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RTRaffaella Tulino
Raffaella Tulino
ABAgnesska C. Benjamin
Agnesska C. Benjamin
NJNelly Jolinon
Nelly Jolinon
DSDonna L. Smith
Donna L. Smith
ECEduardo Chini
Eduardo Chini
GBGillian P. Bates
Gillian P. Bates
[This corrects the article DOI: 10.1371/journal.pone.0145425.].